InMed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results and Provides Business Update
VANCOUVER, British Columbia, Sept. 23, 2022 (GLOBE NEWSWIRE) — InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq:INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today reported financial results for the fiscal year ended June 30, 2022.
Related news for (INM)
- Don’t Miss Out: MoBot’s Latest Stock Updates 06/17/25 04:00 AM
- Siyata Mobile’s $160M Core Gaming Merger Closing Date Nears Without Advance Notice
- MoBot alert highlights: NASDAQ: INM (06/02/25 07:00 AM)
- InMode Response Letter to DOMA by Moshe Mizrahy, CEO, Dated May 28, 2025
- Today’s Top Performers: MoBot’s Market Review 05/14/25 02:00 PM